|
|
||||||||


Divisions of
* Molecular Immunology and
Molecular Neuroendocrinology, The National Institute for Medical Research, Mill Hill, London, United Kingdom
| Abstract |
|---|
|
|
|---|
-producing CD8 T cells in the pituitary gland and a
slight reduction in pituitary GH levels, no effect on growth was
observed. Thus, CD8 T cells have access to the neuroendocrine system
and get fully activated in the absence of CD4 help, but Ag recognition
in this location causes autoimmune pathology only in the presence of
excessive CD8 T cell numbers. | Introduction |
|---|
|
|
|---|
We were interested to analyze to what extent the immune system has access to Ag expressed in the neuroendocrine system and what the consequences of recognition might be. To test this, we made use of a construct containing the extensively characterized human growth hormone (hGH) promoter and locus control region (LCR) (22). The hGH LCR reliably directs position-independent, copy number-dependent transgene expression in the pituitary somatotrophs of transgenic mice. This system is therefore ideal for studies of bona fide tissue-specific Ag expression, avoiding the pitfalls with tissue-specific promoters lacking major regulatory control elements, such as transgenic promoters that frequently show ectopic expression in the thymus or position effect variegation. The hGH LCR has been shown to direct heterologous proteins efficiently to the regulated growth hormone (GH) secretory pathway using GH signal peptide and N-terminal sequences (22, 23). The pituitary gland is a highly vascularized peripheral organ outside the blood brain barrier, with both arterial and venous blood supplies. Releasing hormones, secreted from hypothalamic nerve terminals into capillaries in the external zone of the median eminence, are collected and delivered via the hypophysial portal veins to the anterior pituitary gland. The endothelial cells lining the pituitary sinusoids provide little barrier to the passage of secreted proteins from the endocrine cells to the bloodstream, which drain rapidly via the cavernous sinus to the jugular veins. However, very little is known of the lymphatic drainage of the pituitary.
We introduced influenza nucleoprotein (NP), containing an epitope recognized by H-2Db-restricted CD8 T cells from the F5 TCR transgenic strain (24), into a cosmid construct containing the full hGH LCR, promoter, and signal sequences, and generated transgenic mice. With this construct, NP should be stored in secretory vesicles of somatotrophs and released in a pulsatile manner, generating high local Ag concentrations in the anterior pituitary sinusoids that are rapidly diluted in the systemic blood volume.
Tissue-specific expression of NP in somatotrophs resulted in activation of monoclonal F5 CD8 T cells in the absence of CD4 T cell help. In double-transgenic mice with both influenza NP-specific T cells and cognate Ag (NP), T cell activation led to rapid autoimmune destruction of GH-producing cells and a dwarf phenotype. We found that NP secreted locally in the pituitary gland was cross-presented by DC and gained access to CD8 T cells in peripheral lymphoid organs draining the pituitary gland. Adoptively transferred F5 T cells first proliferated in lymph nodes and subsequently migrated to the pituitary gland.
| Materials and Methods |
|---|
|
|
|---|
Rag1-/- H-2b (Rag-/-), F5 Rag1-/- H-2b (F5) mice (24), and F5 Rag1-/- H-2b mice expressing green fluorescent protein (GFP) under control of the CD2 promoter in all T cells (GFP-F5) were bred in the animal facilities of the National Institute for Medical Research in accordance with established guidelines. The 48-Rag1-/- H-2b mice and the double-transgenic F1 intercross with F5 are termed 48-Rag-/- and 48-Rag-/--F5 throughout this work. Mice transgenic for NP ± the F5 TCR on a polyclonal C57BL/10 background are called 48-B10 and 48-B10-F5.
Construction of the 48GH-NP cosmid for generating transgenic animals
A PCR fragment encoding influenza A/NT/60/68 NP (GenBank
Accession J02137) was generated. This NP gene fragment was flanked by
PvuII restriction enzyme sites (5'-CAGCTG-3') and contained
the sequence encoding a truncated NP protein lacking the ATG
translation start codon (aa 2, 327498), and the influenza
hemagglutinin (HA) epitope YPYDVPDYA. The sense and antisense primers
had the following sequences, respectively: 5'-CAGCTGGCGCTGGTGTGGATGG-3'
and
5'-CAGCTGCCAGCGTAGTCTGGGACGTCGTATGGGTAATTGTCGTACTCCTCTGC-3'.
The antisense primer contained the sequence encoding the last 6
C-terminal aa of NP, the HA epitope, and a PvuII site. A
plasmid containing the truncated NP gene (MI3) was used as the PCR
template (25). The PCR product was subcloned into
pGEMT-Easy (Promega, Madison, WI) for sequencing, and pRSET
(Invitrogen, Carlsbad, CA) for protein expression. The NP PCR product
had the correct sequence and encoded a protein of the predicted size
that could be detected on a Western blot with an anti-HA Ab (data
not shown). The chimeric 48GH-NP sequence was generated when the NP PCR
fragment was ligated into the PvuII sites of a modified hGH
genomic clone containing an MluI linker (Fig. 1
A). The 48GH-NP insert contains a genomic sequence encoding
the first 48 aa of the hGH gene product (signal peptide and N-terminal
22 residues of hGH) fused in frame with the NP cDNA. The hGH gene
sequences of a 40-kb cosmid (B2K) (23) were excised as a
single MluI fragment and replaced with the
MluI-linked 48GH-NP sequence to give the cosmid cos48GH-NP.
Thus, the final cosmid contained a
40-kb insert containing the hGH
LCR, 5' and 3' untranslated sequences of the hGH gene driving
expression of the 48GH-NP fusion protein.
|
Cosmid cos48GH-NP DNA was linearized by NotI digestion. The fragment was purified by gel extraction and column elution (Schleicher & Schuell, Dassel, Germany) and adjusted to a concentration of 15 ng/µl in 0.5 mM EDTA, 1 mM Tris-HCl, pH 7.5. Transgenic mice were generated by pronuclear microinjection of fertilized oocytes of superovulated Rag-/- H-2b mice, followed by oviductal transfer into pseudopregnant recipients.
Genotyping of transgenic animals
Genomic DNA from tail biopsies was analyzed for transgene DNA by a standard PCR using NP-specific primers: 5'-GCTCACCTAGCGGCAATGGC-3' and 5'-AGGCCCTCTGTTGATTAGTGTTTC-3'. Thirty-five cycles of amplification were performed under the following conditions: 94°C for 45 s, 52°C for 30 s, and 72°C for 45 s per cycle.
Immunocytochemistry
Mouse pituitaries were embedded in OCT compound (BDH, Poole, U.K.) and frozen. Tissue sections (6 µm) were collected on Superfrost Plus slides (BDH), air dried, and fixed in acetone for 5 min before immunostaining. Sections were incubated with blocking solution (20% normal mouse serum in PBS) and then with primary Abs against either cell surface markers, GH or HA, for 1 h at room temperature. Sections were washed in PBS and incubated with secondary and tertiary reagents (when necessary). Reagents and Abs were: rat anti-HA FITC (3F10; Roche, Basel, Switzerland); monkey anti-rat GH (National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD); rat anti-mouse CD3 (KT3); hamster anti-mouse CD11c biotin (N418); donkey anti-rat IgG FITC (Jackson ImmunoResearch, West Grove, PA); biotinylated goat anti-human Ab (Jackson ImmunoResearch); streptavidin FITC (BD Biosciences, San Jose, CA); and streptavidin Texas Red (BD Biosciences). Stained sections were mounted in Fluoromount (BDH) and viewed with either a conventional or confocal fluorescence microscope.
Histology
Pituitaries were fixed in phosphate-buffered 4% paraformaldehyde, pH 7.2, and embedded in paraffin. Sagittal sections (10 µm) were cut, dewaxed, and stained with H&E.
FACS analysis
Single cell suspensions of pituitaries, spleen, or lymph nodes
were stained by sequential incubations on ice with Abs specific for
cell surface markers, followed by streptavidin-fluorochrome conjugates
when necessary. Nonspecific staining via FcR binding was blocked by
initial incubation with anti-FcR Ab clone 2.4G2. Cell data were
acquired on a FACSCalibur machine (BD Biosciences) with CellQuest
software. Abs and secondary reagents are as follows: CD8 PE; TCR
APC
(clone H57); CD44 biotin; CD4 FITC; streptavidin Cy7PE (all BD
Biosciences). Intracellular IFN-
was detected in T cells following a
4-h stimulation with phorbol dibutyrate (50 ng/ml), ionomycin (50
ng/ml), and brefeldin A (10 µg/ml) in complete IMDM at 37°C. Cells
were washed, stained for cell surface markers (as above), and
then fixed in 1% paraformaldehyde for 15 min on ice and permeabilized
in 1% Nonidet P-40 for 3 min on ice. Cells were incubated with rat
anti-IFN-
PE or rat IgG1 PE Ab isotype control (BD
Biosciences).
Adoptive transfer
A total of 25 x 106 GFP-F5 CD8 T cells were injected i.v. into Rag-/-, 48-Rag-/-, B10, 48-B10, or double-transgenic 48-Rag-/--F5 hosts. To monitor cell proliferation, F5 T cells were labeled with CFSE (Molecular Probes, Eugene, OR), as previously described (26). Briefly, pooled spleen and lymph node cells were incubated at 37°C for 10 min at a cell density of 107/ml in 2 µM CFSE and washed thoroughly before i.v. injection.
Radioimmunoassays
Mouse GH in pituitary extracts was assayed by RIA, as previously described for the rat (27), using mouse reagents kindly provided by National Institute of Diabetes and Digestive and Kidney Diseases. Unless otherwise stated, data are shown as mean ± SD.
| Results |
|---|
|
|
|---|
To direct expression of influenza NP to pituitary somatotrophs, we
used a construct containing the GH promoter and the well-characterized
hGH LCR. The 48GH-NP transgenic line was generated by injecting a 40-kb
cosmid clone containing a genomic sequence encoding the signal peptide
and initial N-terminal sequences of the hGH gene fused to a truncated
influenza NP (aa 2, 327498; Fig. 1
A) with a C-terminal HA tag.
Fertilized eggs from Rag-/-
H-2b mice were injected, and one founder female
was bred to Rag-/- H-2b
to generate the 48-Rag-/- line. Transgene
expression was visualized by staining pituitary sections for the HA tag
and colocalized with GH expression in somatotrophs. NP appeared to be
packaged into secretory granules (Fig. 1
B). Mice carrying
the 48GH-NP transgene showed normal weight gain; pituitary GH levels
were comparable to those of nontransgenic
Rag-/- mice; and
48-Rag-/- mice exhibited no phenotypic changes
in their pituitary glands (Fig. 2
). Thus,
transgenic expression of NP does not interfere with normal somatotroph
physiology.
|
We crossed 48-Rag-/- mice with the F5
strain that expresses a monoclonal population of CD8 T cells specific
for influenza NP epitope 366374, to investigate whether NP-specific T
cells would have access to Ag expressed in the pituitary gland.
Analysis of the thymus from double-transgenic mice revealed that
absolute numbers of T cells, composition of thymocyte subpopulations,
and levels of TCR expression were similar to those found in normal F5
littermates (data not shown). This confirms the absence of ectopic
expression, as has been consistently observed with the hGH LCR by
others. Although GH expression was reported in the subcapsular cortex
of human thymus (28), it appears that expression in such
locations has no influence on T cell development, because this would
have resulted in at least a degree of negative selection in developing
F5 thymocytes. Tissue-specific expression of NP in the pituitary gland
of mice transgenic for both NP and the F5 TCR was manifested by a
striking dwarf phenotype (Fig. 3
B, inset). In
normal mice, GH-dependent weight increase is evident from 4 wk after
birth, but the 48-Rag-/--F5 double-transgenic
mice failed to gain weight from about this time onward (Fig. 3
A). A dramatic reduction of GH levels in the pituitaries of
double-transgenic mice was already evident at 4 wk of age. GH decreased
to almost undetectable levels (<0.1% of normal) by 8 wk of age (Fig. 3
B). Double-transgenic mice on a
Rag-/- background also showed reduced levels of
other hormones produced in the anterior pituitary gland, including
prolactin (Fig. 3
C) and thyroid-stimulating hormone (Fig. 3
D). Severe reductions in GH levels were also evident in
48-B10-F5 mice on a Rag+ background (Fig. 3
E), although not as severe as that seen in
48-Rag-/--F5 mice; this was reflected in a less
dramatic effect on growth (data not shown). These differences were
presumably because of a lower frequency of F5 T cells in the
Rag+/- mice, probably resulting in a delayed
onset of somatotroph destruction.
|
(Fig. 4
|
To follow the sequence of events leading to destruction of
GH-producing somatotrophs, we performed adoptive transfers of naive T
cells from GFP-F5 mice. Transfers were done into
transgenic (48-Rag-/-,
48-Rag-/--F5, or 48-B10) or nontransgenic
(Rag-/-, F5, or B10) hosts. Seven days after
transfer into 48-Rag-/- (Fig. 5
A) or double-transgenic
48-Rag-/--F5 (Fig. 5
B) mice, a
proportion of the GFP-positive T cells found in cervical lymph nodes
had up-regulated the activation marker CD44. GFP-F5 T cells transferred
into nontransgenic Rag-/- adoptive hosts did
not up-regulate CD44 at this early time point, because homeostatic
expansion of F5 T cells in lymphopenic hosts does not result in
acquisition of activation markers early after transfer
(29) (Fig. 5
C). A similar picture was found in
superficial cervical, deep cervical, axillary, brachial, inguinal, and
mesenteric lymph nodes (not shown). Seven days after transfer, no cells
were found in the pituitary glands and very few in the spleen of
48-Rag-/- hosts (not shown), indicating an
early time point of activation in the regional lymph nodes. Activated T
cells were first detected in the pituitary gland of
48-Rag-/- mice (and not
Rag-/- controls) 21 days after transfer (Fig. 5
I), whereas double-transgenic hosts showed an earlier
influx of GFP-F5 T cells by 7 days after transfer (Fig. 5
J),
presumably because of the already severe inflammatory conditions
prevalent in these hosts from an early age (see also the large
population of GFP-negative, host-derived CD8+
CD44+ T cells in this location). Therefore,
despite the dramatic destruction of somatotrophs in
48-Rag-/--F5 mice, there is clearly sufficient
ongoing Ag expression for activation of further T cells.
|
(Fig. 5
Despite the continuous and long-term presence of transferred
Ag-specific T cells in peripheral lymphoid organs and the pituitary
gland, no fulminant autoimmune pathology was observed, and GH levels
were only slightly lower than in control animals (Fig. 5
D).
| Discussion |
|---|
|
|
|---|
Although it has been shown previously that systemic administration of soluble Ag in very high doses can lead to cross-presentation by DC and activation of CD8 T cells (13, 31, 32), little is known about the recognition of endogenously synthesized and locally secreted Ag by CD8 T cells. In fact, given the extraordinarily large doses of soluble Ag necessary to achieve activation of CD8 T cells, we had anticipated that F5 CD8 T cells would remain ignorant of soluble NP expressed in the pituitary gland, unless they were specifically activated by Ag in an optimal immunogenic form, e.g., following infection with influenza virus. However, the local concentration of NP, mimicking that of GH, as anticipated by its localization in secretory granules, would be orders of magnitude higher than levels found in peripheral blood. In contrast, NP stores in the anterior pituitary will be somewhat lower than those of GH, because GH has specific sequences mediating zinc-dependent aggregation and packing to form a dense granule protein core (33), resulting in a higher GH concentration than that of a heterologous protein targeted to the same granule (23).
The anterior pituitary gland contains numerous DC that have been
ascribed a role in regulation of endocrine cells (34).
They are identified by their morphology, high expression of MHC class
II, and the capacity to stimulate T cells in a MLR. The presence of DC
in the vicinity of somatotrophs secreting NP makes uptake of soluble NP
and processing in the MHC class I pathway feasible. We designed the
adoptive transfer experiments shown in Fig. 5
with the aim to determine
where T cell activation takes place and whether this can cause
autoimmune pathology. The kinetics of T cell activation following their
transfer into 48-Rag-/- mice suggests that
migratory DC carry NP internalized and cross-processed with MHC class I
from the pituitary gland into lymphoid organs for activation of T
cells. This is in agreement with earlier data showing cross-priming of
OVA-specific CD8 T cells in lymph nodes draining the pancreas that
expressed OVA as a transgene (35). Whether the migratory
DC present Ag to T cells directly or are themselves phagocytosed by
resident DC (36) is unclear. It is unlikely that Ag gains
access to lymphoid organs in soluble form. First, its concentration in
blood, like that of GH, is far below the amount required for
cross-presentation by DC (13). Second, despite the much
higher blood supply for the spleen (37), activated T cells
were first detected in lymph nodes and were not apparent in the spleen
until the later stages after they had already entered the pituitary
gland. Third, there is no evidence of Ag access to the thymus via the
blood judged by unimpaired development of F5 thymocytes.
The current view is that cross-presentation of Ag in the absence of
danger signals, resembling pathogen-associated molecules, fails to give
maturation signals to T cells (19, 38, 39) and favors
tolerance induction rather than activation of CD8 T cells (20, 40). The expression of NP in somatotrophs of
48-Rag-/- transgenic mice has no discernible
adverse effect on these cells, as shown by their normal morphology, GH
concentrations, and unaffected growth rates. However, the type and
concentration of Ag, as well as the affinity and frequency of
responding CD4 or CD8 T cells will influence whether activation and
autoimmunity or tolerance are the outcome of peripheral Ag expression
(1, 2, 4, 41, 42, 43). It is likely that the high frequency of
Ag-specific T cells in double-transgenic
48-Rag-/--F5 mice can also overcome the
requirement for T cell help (44, 45) that was previously
shown to prevent T cell deletion and favor autoimmunity
(10). Infiltration of the pituitary gland was also
observed following transfer of small numbers of T cells. Despite being
fully activated to IFN-
secretion, they caused only a marginal
reduction in GH levels that did not result in a dwarf phenotype (Fig. 5
, D and L). This suggests that the
reduced influx of Ag-specific activated T cells, as would more closely
resemble physiological conditions in a polyclonal setting, does not
cause the fulminant pathology seen in the double-transgenic mice.
Preliminary data at a later time point, however, indicate that
eventually significant damage to the pituitary does occur. Autoimmune
reactions against the anterior pituitary gland arising either
spontaneously in patients (46) or following injections of
pituitary homogenate in rats (47) have been described, but
were only correlated with Abs to pituitary constituents. Our data
indicate that neuroendocrine self Ag secreted in a hormone-like fashion
is indeed visible for CD8 T cells and under certain conditions can
cause autoimmune activation.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Abbreviations used in this paper: DC, dendritic cell; GFP, green fluorescent protein; GH, growth hormone; HA, hemagglutinin; hGH, human GH; LCR, locus control region; NP, nucleoprotein. ![]()
Received for publication August 21, 2002. Accepted for publication October 17, 2002.
| References |
|---|
|
|
|---|
v
5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359.
cell neo-antigen. Immunity 2:573.[Medline]
This article has been cited by other articles:
![]() |
S.-C. Tzou, I. Lupi, M. Landek, A. Gutenberg, Y.-M. Tzou, H. Kimura, G. Pinna, N. R. Rose, and P. Caturegli Autoimmune Hypophysitis of SJL Mice: Clinical Insights from a New Animal Model Endocrinology, July 1, 2008; 149(7): 3461 - 3469. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Stamou, J. de Jersey, D. Carmignac, C. Mamalaki, D. Kioussis, and B. Stockinger Chronic Exposure to Low Levels of Antigen in the Periphery Causes Reversible Functional Impairment Correlating with Changes in CD5 Levels in Monoclonal CD8 T Cells J. Immunol., August 1, 2003; 171(3): 1278 - 1284. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |